2026 Q2 Portfolio Activity
In 2026 Q2, B Group, Inc. maintained a portfolio of 22 distinct positions. The most significant new addition was INVESCO QQQ TR, now representing 17.29% of the total fund value. They heavily accumulated shares in NRX PHARMACEUTICALS INC, increasing the position by 36.4%. The fund also reduced its exposure to SPYRE THERAPEUTICS INC by 30.0%.
Position History
hover any row below to update
Loading…
Total Positions
22
Quarter
2026 Q2
Top Holding
N/A (17.3%)
Top 10 Concentration
79.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-22 of 22
B Group, Inc. Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
N/A
PUT
INVESCO QQQ TR
|
|
PUT Option | 17.29% | — |
#1
Prev: #—
|
9.5 |
—
|
50,000 | — |
NEW
|
50,000 | $36,820,000 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ADMA
ADMA BIOLOGICS ...
|
Healthcare | 12.82% | 21.43% |
#2
1
Prev: #1
|
6.0 |
—
|
55,000 | 1.7% |
P
S
|
3,262,542 | $27,307,477 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 11.20% | 14.81% |
#3
1
Prev: #2
|
6.0 |
—
|
no change | no change |
P
S
|
11,414,285 | $23,855,856 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NRXP
NRX PHARMACEUTI...
|
Healthcare | 7.86% | 4.74% |
#4
3
Prev: #7
|
6.1 |
—
|
1,091,767 | 36.4% |
P
S
|
4,091,767 | $16,735,327 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 7.16% | — |
#5
Prev: #—
|
6.9 |
—
|
610,169 | — |
NEW
|
610,169 | $15,254,225 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 5.76% | 5.97% |
#6
Prev: #6
|
3.3 |
—
|
no change | no change |
P
S
|
1,800,556 | $12,261,786 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 5.22% | 7.94% |
#7
4
Prev: #3
|
3.1 |
—
|
no change | no change |
P
S
|
33,237 | $11,127,415 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CLLS
CELLECTIS S A
|
Healthcare | 4.62% | 7.71% |
#8
4
Prev: #4
|
2.8 |
—
|
no change | no change |
P
S
|
3,281,501 | $9,844,503 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 4.02% | 6.28% |
#9
4
Prev: #5
|
2.6 |
—
|
no change | no change |
P
S
|
450,646 | $8,562,274 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 3.53% | 4.56% |
#10
2
Prev: #8
|
3.4 |
—
|
12,500 | 9.8% |
P
S
|
140,000 | $7,513,800 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 3.35% | 2.73% |
#11
3
Prev: #14
|
2.3 |
—
|
no change | no change |
P
S
|
75,000 | $7,137,750 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IOVA
IOVANCE BIOTHER...
|
Healthcare | 2.93% | 3.90% |
#12
3
Prev: #9
|
2.2 |
—
|
no change | no change |
P
S
|
1,500,000 | $6,240,000 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.92% | 3.74% |
#13
3
Prev: #10
|
1.2 |
—
|
-30,000 | -30.0% |
P
S
|
70,000 | $6,214,600 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 2.55% | 2.96% |
#14
1
Prev: #13
|
3.5 |
—
|
166,667 | 27.9% |
P
S
|
764,243 | $5,426,125 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 2.27% | 3.61% |
#15
3
Prev: #12
|
1.9 |
—
|
no change | no change |
P
S
|
175,706 | $4,828,401 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 2.22% | 3.65% |
#16
5
Prev: #11
|
1.9 |
—
|
no change | no change |
P
S
|
67,500 | $4,738,500 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 2.12% | 2.10% |
#17
1
Prev: #16
|
1.8 |
—
|
no change | no change |
P
S
|
135,000 | $4,507,650 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SGHT
SIGHT SCIENCES ...
|
Healthcare | 1.72% | 2.71% |
#18
3
Prev: #15
|
1.7 |
—
|
no change | no change |
P
S
|
970,000 | $3,656,900 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
FHTX
FOGHORN THERAPE...
|
Healthcare | 0.46% | 0.36% |
#19
1
Prev: #18
|
3.2 |
—
|
98,000 | 96.1% |
P
S
|
200,000 | $976,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 0.00% | 0.15% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-26,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.00% | 0.19% |
Sold All 😨
(Was: #19) |
0.0 |
—
|
-7,500 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 0.00% | 0.47% |
Sold All 😨
(Was: #17) |
0.0 |
—
|
-7,500 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-22 of 22 holdings